第八届进博会丨进博“加速度” “进博宝宝”从展品变商品推动1型糖尿病防治迈向“生态共建”

Core Viewpoint - Sanofi's Teriparatide has transitioned from an exhibit to a commercial product, marking a significant advancement in the treatment of Type 1 diabetes in China, with its official approval by the National Medical Products Administration in September [1] Group 1: Product Development and Approval - Teriparatide is an innovative drug aimed at delaying the progression of Type 1 diabetes [1] - The drug's journey included its debut at the China International Import Expo and a pilot program in Boao, leading to its market approval [1] Group 2: Ecosystem Establishment - The "China Type 1 Diabetes Diagnosis and Treatment Ecosystem" was officially established at this year's expo [1] - Partners within the ecosystem will focus on enhancing clinical research, early screening models, comprehensive disease management, and digital integration to advance Type 1 diabetes prevention and treatment [1]